DXCM DEXCOM INC.

Alberta Government Lifts Age Restrictions on Continuous Glucose Monitors (CGM) and Eligible Albertans With Type 1 or Type 2 Diabetes Can Now Access Dexcom G7 CGM

Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing technology, is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) System has now been added to the Alberta Drug Benefit List. In addition, the Alberta government has expanded the eligibility criteria* to also include adults ages 18 and older.

This press release features multimedia. View the full release here:

Alberta residents living with type 1 or type 2 diabetes who meet the eligibility criteria are now covered for Dexcom G7 (Photo: Business Wire)

Alberta residents living with type 1 or type 2 diabetes who meet the eligibility criteria are now covered for Dexcom G7 (Photo: Business Wire)

Alberta residents living with type 1 or type 2 diabetes who are enrolled in a government-sponsored health benefit plan and meet the eligibility criteria* below may now receive coverage for Dexcom G7:

  • Under 18 years of age: requiring the ongoing use of any insulin OR insulin pump therapy.
  • 18 years of age and older: requiring the ongoing use of insulin pump therapy, OR a basal and bolus insulin, OR a premixed insulin.

“Canadians living with any type of diabetes understand the challenges that come with management of the condition. Dexcom G7 has been designed to make daily management easier and to help improve users' day-to-day lives – whether they’re a recently diagnosed adolescent or an adult who’s lived with the condition for decades,” said André Côté, Vice President and General Manager of Dexcom Canada. “We’re thrilled that the government of Alberta recognizes this and is introducing public coverage for eligible residents that includes both adults and children living with type 1 or type 2 diabetes on intensive insulin therapy.”

Dexcom G7 offers a better way to help users gain greater control of their glucose levels and is clinically proven to lower A1C for people living with type 1 diabetes and type 2 diabetes.1-5 Features like its quick sensor warm-up time, a predictive Urgent Low Soon alert, and wide range of compatible digital health apps differentiate it amongst other available CGM systems in Canada, providing users with a simple, accurate6 and effective way to manage their diabetes day-to-day.

"The importance and value of continuous glucose monitoring (CGM) for people living with diabetes requiring insulin treatment is underscored by Canadian and international clinical practice guidelines," said Dr. Peter Senior, Endocrinologist and Director of the Alberta Diabetes Institute. "As a diabetes specialist working with patients, I have seen the benefits of CGM and the challenges faced by those who couldn’t afford it. Ensuring equitable access to CGM technology is a significant and important step forward for diabetes care in Alberta.”

Across Canada, coverage for Dexcom’s leading CGM technology has grown significantly over the last few years. This announcement brings Alberta on par with British Columbia, Manitoba, New Brunswick, Nova Scotia, Prince Edward Island and Yukon in terms of making diabetes technology like Dexcom CGM available to a broader group of those who can benefit from it.

Albertans on any type of insulin who have private insurance or are covered by the Non-Insured Health Benefits (NIHB) federal program have access to Dexcom G7 through those plans.‡.

To learn more about Dexcom G7 and details about public or private insurance plan coverage, please visit .

About Dexcom

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit .

_______________________________________

1 Beck RW, et al. JAMA. 2017;317(4):371-378.

2 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374.

3 Martens T, et al. JAMA. 2021;325(22):2262-2272.

4 Laffel LM, et al. JAMA. 2020;323(23):2388-2396.

5 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7.

6 Dexcom, data on file, 2024.

* For detailed coverage criteria, please visit .

† To view a list of eligible government-sponsored health benefit plans, please visit .

‡ Eligibility and coverage vary by policy, plan, and payor.

EN
17/12/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DEXCOM INC.

 PRESS RELEASE

Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medi...

EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East." The report surveyed over 2,500 people, made up of individuals with Type 2 diabetes and healthcare professionals, from Germany, Italy, the Netherlands, Saudi Arabia, Spain and the United Kingdom. The findings provide valuable insights into access to care and perceptions of diabetes technology. During the conference, first-ever accuracy a...

Research Team ACF
  • Research Team ACF

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

 PRESS RELEASE

Dexcom Appoints Renée Galá to Board of Directors

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March 6, 2025. Ms. Galá is an accomplished executive with significant financial, strategic and operational leadership experience across the life sciences sector. She currently serves as President and Chief Operating Officer of Jazz Pharmaceuticals Public Limited Company, a global biopharmaceutical company with greater than $4 billion in total revenues in 2024 whose purpose is to innovate to transform the lives of p...

 PRESS RELEASE

Dexcom Announces Upcoming Conference Presentation

SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that management will present an update on the company at the 46th Annual Raymond James Institutional Investors Conference on Tuesday, March 4th. The live presentation is scheduled to begin at approximately 10:25 AM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at and will be archived there for future reference. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneere...

 PRESS RELEASE

Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: Revenue grew 8% year-over-year to $1.114 billion on a reported basis and 8% year-over-year on an organic1 basis. U.S. revenue grew 4% and international revenue grew 17% on a reported basis and 19% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $188.9 million or 17.0% of revenue, a decrease of 400 basis points compared to the fourth quarter of 2023. Non-...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch